Search clinical trials for: Nk1 Antagonist and SSRI

Total 471643 results

Sanofi

Completed

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

Overactive Bladder

United States
St. Joseph's Healthcare Hamilton
University Health Network, Toronto

Unknown

Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour (AHIMSA-1)

Aggression

Canada
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
GlaxoSmithKline

Completed

28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)

Depressive Disorder

Germany
Sanofi

Completed

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study (NICE)

Ulcerative Colitis | Inflammatory Bowel Disease

Canada, Brazil, Russian Federation, Italy, Spain, Sweden, Estonia, Singapore, Belgium, Czech Republic, Argentina, Hungary, Chile, South Africa
GlaxoSmithKline

Completed

First Study in Humans With GSK206136 (NSB101909)

Depressive Disorder and Anxiety Disorders

United Kingdom
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

Alcohol Dependence | Cocaine Dependence

United States
Sharon Walsh
National Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLC

Completed

Aprepitant Effects on Oxycodone Response

Narcotic Abuse

United States
GlaxoSmithKline

Completed

Food and Relative Bioavailability Study (Food/rel BA)

Depressive Disorder

Italy
GlaxoSmithKline

Completed

GW679769 In Fibromyalgia

Depressive Disorder | Depression | Fibromyalgia
Arun Gupta
Cambridge University Hospitals NHS Foundation Trust

Withdrawn

Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury (NK1)

Traumatic Brain Injury
GlaxoSmithKline

Completed

A Repeat Dose Positron Emission Tomography Study With GSK1144814 (NK1 NK3 PET)

Schizophrenia

United Kingdom
Cairo University

Not yet recruiting

Effect of Commiphora Myrrh Solution as a Root Canal Irrigant on Post Operative Pain and Bacterial Load Reduction in Necrotic Tooth

Necrotic Pulp
Vyne Therapeutics Inc.

Completed

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Prurigo Nodularis

Germany
GlaxoSmithKline

Completed

First Study in Humans With GSK424887

Depressive Disorder and Anxiety Disorders

United Kingdom
National Institute of Mental Health (NIMH)

Completed

Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ

Healthy | Panic Disorder

United States
The Scripps Research Institute
National Institute on Drug Abuse (NIDA)

Completed

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

Alcohol Dependence | Cannabis Dependence | Alcohol Use Disorder | Cannabis Use Disorder

United States
Baylor College of Medicine
National Institute of Mental Health (NIMH)

Completed

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

PTSD

United States
University of Michigan Rogel Cancer Center

Active, not recruiting

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Gynecologic Cancer

United States
University of Virginia
National Institute on Drug Abuse (NIDA)

Completed

Medications Development for the Treatment of Cannabis Related Disorders (MTC)

Cannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine Withdrawal

United States
Xiao Wang

Recruiting

Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen

Estrogen | Postmenopausal Depression

China
Astellas Pharma Global Development, Inc.

Recruiting

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (OPTION-VMS)

Hot Flashes

United States
Takeda

Not yet recruiting

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Major Depressive Disorder
Göteborg University
Arvid Carlsson Research AB

Recruiting

OSU6162 as add-on in SSRI/SNRI-resistant Depression (ODEN)

Depressive Disorder | Depression | Depressive Disorder, Treatment-Resistant | Depressive Episode | Recurrent Depressive Disorder | Recurrent Depression

Sweden
Zhenghui YI

Not yet recruiting

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems

Depression

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Metastatic Malignant Neoplasm in Lymph Node | Prostate Ductal Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
Pachankis, Yang I., M.D.
First Affiliated Hospital of Chongqing Medical University

Completed

Detoxification From the Lipid Tract

COVID-19 Vaccine Adverse Reaction

China
University Hospital, Basel, Switzerland

Completed

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects (SERT-LSD)

Healthy

Switzerland
Small Pharma Ltd

Completed

SPL026 With or Without SSRIs in Participants With MDD

Major Depressive Disorder

United Kingdom
Azienda Ospedaliera Universitaria Integrata Verona
University of Catania

Completed

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment (VESPA)

Major Depressive Disorder

Italy
Shanghai Mental Health Center

Withdrawn

Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder

Obsessive-Compulsive Disorder
Florida Gulf Coast University

Completed

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

Major Depressive Disorder

United States
University Hospital Bispebjerg and Frederiksberg

Completed

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Stress Urinary Incontinence | Fecal Incontinence

Denmark
Emory University
National Institute of Mental Health (NIMH)

Completed

The ISLAND Study: InSuLa Assessed Needs for Depression (ISLAND)

Depression

United States
University of Texas Southwestern Medical Center
Takeda Pharmaceuticals North America, Inc.

Terminated

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon (TAKEDA)

Insomnia | Major Depressive Disorder

United States
Bayer

Completed

Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN) (EPISAT)

Stroke | Coronary Heart Disease | Ischemic Heart Disease | Secondary Prevention

United Kingdom
University of Texas Southwestern Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Antidepressant Treatment at an Inner City Asthma Clinic

Depression | Asthma

United States
Johns Hopkins University
National Institute of Mental Health (NIMH)

Completed

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (ParaFlu)

HIV Associated Neurocognitive Disorder

United States
University of Aarhus

Completed

Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight (LBW-SSRI)

Cardiovascular Disease | Anxiety Disorders | Insulin Resistance | Type 2 Diabetes | Low Birth Weight | Melancholic Depression

Denmark
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Serbia, Slovakia, Estonia
ViiV Healthcare
Pfizer

Completed

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Healthy Subjects

United States
Boston University
National Institute of Mental Health (NIMH)

Completed

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

Autistic Disorder

United States
Research Foundation for Mental Hygiene, Inc.
National Institute of Mental Health (NIMH)

Completed

Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

Posttraumatic Stress Disorder

United States
Yale University

Completed

Naltrexone & SSRI in Alcoholics With Depression/PTSD

Depression | PTSD | Alcoholism

United States
Samsung Medical Center

Unknown

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

Depression | Adverse Reaction to Drug

Korea, Republic of
Samsung Medical Center

Unknown

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness (PG)

Depression | Antidepressant Drug Adverse Reaction

Korea, Republic of
Samsung Medical Center

Unknown

Predict Antidepressant Responsiveness Using Pharmacogenomics

Depression | Depressive Symptoms

Korea, Republic of
Samsung Medical Center

Unknown

Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype

Depression

Korea, Republic of
State University of New York - Upstate Medical...

Completed

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

General Anxiety Disorder, Social Anxiety Disorder

United States
Massachusetts General Hospital
University of Alabama at Birmingham

Completed

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Major Depressive Disorder

United States

Search clinical trials for: Nk1 Antagonist and SSRI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations